Homing and Engraftment of Hematopoietic Stem Cells Following Transplantation: A Pre-Clinical Perspective
Curr Oncol. 2024 Jan 23;31(2):603-616. doi: 10.3390/curroncol31020044.ABSTRACTHematopoietic stem-cell (HSC) transplantation (HSCT) is used to treat various hematologic disorders. Use of genetically modified mouse models of hematopoietic cell transplantation has been critical in our fundamental understanding of HSC biology and in developing approaches for human patients. Pre-clinical studies in animal models provide insight into the journey of transplanted HSCs from infusion to engraftment in bone-marrow (BM) niches. Various signaling molecules and growth factors secreted by HSCs and the niche microenvironment play critical...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tanvir Hasan Ajay Ratan Pasala Dhuha Hassan Justine Hanotaux David S Allan Harinad B Maganti Source Type: research
Radiation Segmentectomy for Hepatocellular Carcinoma
Curr Oncol. 2024 Jan 23;31(2):617-628. doi: 10.3390/curroncol31020045.ABSTRACTThe application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCL...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Muhamad Serhal Farnaz Dadrass Edward Kim Robert J Lewandowski Source Type: research
Preparing for and Not Waiting for Surgery
Curr Oncol. 2024 Jan 23;31(2):629-648. doi: 10.3390/curroncol31020046.ABSTRACTCancer surgery is an essential treatment strategy but can disrupt patients' physical and psychological health. With worldwide demand for surgery expected to increase, this review aims to raise awareness of this global public health concern, present a stepwise framework for preoperative risk evaluation, and propose the adoption of personalised prehabilitation to mitigate risk. Perioperative medicine is a growing speciality that aims to improve clinical outcome by preparing patients for the stress associated with surgery. Preparation should begin a...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Andrew Bates Malcolm A West Sandy Jack Michael P W Grocott Source Type: research
The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes
CONCLUSION: Breast cancer patients on chemotherapy face an elevated cardiovascular mortality risk, especially with aggressive subtypes (HER2-enriched, TNBC), advanced age, or HER2+/HR+ cancer receiving long-term treatment.PMID:38392041 | PMC:PMC10887634 | DOI:10.3390/curroncol31020047 (Source: Current Oncology)
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: To àn Minh Ngô Ánh Ngọc Lê D ương Phạm Hoàng Đinh Source Type: research
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)
Curr Oncol. 2024 Jan 24;31(2):660-671. doi: 10.3390/curroncol31020048.ABSTRACTMultidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcome...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Pedro Villarejo Campos Susana S ánchez García Mariano Amo-Salas Esther Garc ía Santos Carlos L ópez de la Manzanara Ana Alberca David Padilla-Valverde Francisco Javier Redondo Calvo Jes ús Martín Source Type: research
Positive Psychological Well-Being in Early Palliative Care: A Narrative Review of the Roles of Hope, Gratitude, and Death Acceptance
Curr Oncol. 2024 Jan 24;31(2):672-684. doi: 10.3390/curroncol31020049.ABSTRACTIn the advanced cancer setting, low psychological functioning is a common symptom and its deleterious impact on health outcomes is well established. Yet, the beneficial role of positive psychological well-being (PPWB) on several clinical conditions has been demonstrated. Early palliative care (EPC) is a recent value-based model consisting of the early integration of palliative care into standard care for solid tumors and hematologic malignancies. While the late palliative care primary offers short-term interventions, predominantly pharmacological...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Elena Bandieri Eleonora Borelli Sarah Bigi Claudia Mucciarini Fabio Gilioli Umberto Ferrari Sonia Eliardo Mario Luppi Leonardo Potenza Source Type: research
Describing and Exploring Coping Strategies among Those Diagnosed with Cancer as an Adolescent or Young Adult: A YACPRIME Study
Curr Oncol. 2024 Jan 24;31(2):685-692. doi: 10.3390/curroncol31020050.ABSTRACTA greater understanding of how young people cope with a cancer diagnosis is needed in order to inform age-appropriate supportive care. This paper describes the coping strategies used and explores relationships between coping strategies and personal, medical, and psychological variables among young adults (YAs) diagnosed with cancer. YAs (n = 547, mean age = 34.05 ± 6.00 years) completed an online survey, including the Brief COPE and measures of psychological functioning. Descriptive statistics and bivariate correlations were computed. Acceptance...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Amanda Wurz Anika Petrella Joshua Tulk Catherine M Sabiston Fiona Schulte Jackie Bender Norma D'Agostino Sharon H J Hou Geoff Eaton Karine Chalifour Sheila N Garland Source Type: research
The Feasibility and Acceptability of a Data Capture Methodology in Pediatric Cancer Patients Treated with Targeted Agents and Immunotherapies
Curr Oncol. 2024 Jan 25;31(2):693-703. doi: 10.3390/curroncol31020051.ABSTRACTAs childhood cancer treatments have improved to include new and innovative agents, the need for more advanced monitoring of their long-term effects and related research has increased. This has resulted in a need for evidence-based research methodologies for the longitudinal care of childhood cancer patients treated with targeted agents and immunotherapies. The rationale for this pilot study was to determine the feasibility and acceptability of a data capture methodology for pediatric, adolescent, and young adult cancer patients treated with targe...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Karim Thomas Sadak Taiwo Opeyemi Aremu Seah Buttar Daniel Van Ly Brenda Weigel Joseph P Neglia Source Type: research
A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada
In conclusion, our findings provide the first comprehensive overview of aUC treatment patterns in Canada following the approval of maintenance immunotherapy, offering insights into the decision-making process and underscoring the importance of evidence-based guidelines in aUC patient management.PMID:38392046 | PMC:PMC10887988 | DOI:10.3390/curroncol31020052 (Source: Current Oncology)
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Feras A Moria Changsu L Park Bernhard J Eigl Robyn Macfarlane Michel Pavic Ramy R Saleh Source Type: research
A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report
CONCLUSIONS: The treatment of metastatic NSCLC remains a significant therapeutic challenge, but the implementation of new therapeutic techniques has expanded the possibilities of achieving complete and durable eradication of the disease.PMID:38392047 | PMC:PMC10888175 | DOI:10.3390/curroncol31020053 (Source: Current Oncology)
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Claudia De Intinis Paolo Izzo Massimo Codacci-Pisanelli Luciano Izzo Daniela Messineo Simone Sibio Monica Campagnol Silvia Lai Marcello Molle Sara Izzo Source Type: research
"The Ability to Go Out into the World Is the Most Important Thing"-A Qualitative Study of Important Exercise Outcomes for People with Lung Cancer
This study aimed to explore the outcomes of exercise that are important to people with lung cancer and their carers. Data collection involved a qualitative methodology including semi-structured interviews and focus groups. Question guide development was informed by the International Classification of Functioning (ICF) framework. Data were analyzed by two researchers with NVivo (v12) software using a conventional content analysis process, followed by directed content analysis to map outcomes to the ICF. Conduct and reporting adhered to COREQ guidelines. Fifteen participants provided data. Most participants had received thei...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Amy Bowman Linda Denehy Cassie E McDonald Lara Edbrooke Source Type: research
Residents and Consultants Have Equal Outcomes When Performing Transrectal Fusion Biopsies: A Randomized Clinical Trial
Curr Oncol. 2024 Jan 29;31(2):747-758. doi: 10.3390/curroncol31020055.ABSTRACTThe aim of our study was to compare the performance of residents vs. consultants in transrectal fusion prostate biopsies (FUS-PBs), as well as patient-reported comfort. Between January 2021 and October 2022, a consecutive series of patients undergoing FUS-PBs were randomized into two groups: (A) FUS-PBs performed by a consultant; (B) FUS-PBs performed by trained residents (>50 procedures). All patients underwent FUS-PBs with 12 systematic cores and 3/6 target cores. The detection rate and number of positive cores in the target lesion were comp...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Beatrice Turchi Riccardo Lombardo Antonio Franco Giorgia Tema Antonio Nacchia Antonio Cicione Antonio Luigi Pastore Antonio Carbone Andrea Fuschi Giorgio Franco Andrea Tubaro Cosimo De Nunzio Source Type: research
Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess the treatment response. Patient characteristics, treatment histories, response rates, progression-free survival, and adverse events were evaluated. Response rates were determined, and adverse events were recorded. Among the 20 patients, 70% were male and 65% had bladder tumo...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Yuki Endo Jun Akatsuka Hayato Takeda Hiroya Hasegawa Masato Yanagi Yuka Toyama Hikaru Mikami Mikio Shibasaki Go Kimura Yukihiro Kondo Source Type: research
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma
Curr Oncol. 2024 Feb 1;31(2):769-777. doi: 10.3390/curroncol31020057.ABSTRACTGastric adenocarcinoma (GAC) continues to be a prevalent worldwide malignancy and a leading cause of cancer death, and it is frequently cited as incurable. Targeted therapy in GAC has lagged behind other solid tumors. The human epidermal growth factor receptor-2 (HER-2) represented the single target in GACs for many years, seen in approximately 20% of patients with advanced GAC. Recent advances in management now include the addition of immunotherapy checkpoint inhibition to select front-line advanced GACs. Unfortunately, outcomes remain poor for m...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Jane E Rogers Jaffer Ajani Source Type: research
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Curr Oncol. 2024 Feb 1;31(2):778-800. doi: 10.3390/curroncol31020058.ABSTRACTMolecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp-a T cell-redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor ...
Source: Current Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Kamil J Synoradzki Natalia Paduszy ńska Malgorzata Solnik Mario Damiano Toro Krzysztof Bilmin El żbieta Bylina Piotr Rutkowski Yacoub A Yousef Claudio Bucolo Sandrine Anne Zweifel Michele Reibaldi Michal Fiedorowicz Anna M Czarnecka Source Type: research